APRE · Aprea Therapeutics Inc
United States · RS rating 19 · As of 2026-11-03
| Price | 0.52 USD |
|---|---|
| 1-day change | +4.9% |
| RS rating (overall / 1M / 3M / 12M) | 19 / 18 / 35 / 15 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 6 / 48 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +31.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +63.2% |
| Market cap (USD) | $10.6M |